|Semaglutide is an agonist of glucagon-like peptide 1 receptor. Semaglutide is a member of the glucagon-like peptide-1 (GLP-1) family, derived from the GLP-1 (sequence 7-37). It decreases blood glucose levels in the mouse model of type 2 diabetes. Semaglutide’s structure differs from liraglutide in two places. The Glycine at position 2 is substituted with Aib (U) and this modification provides significant protection against enzymatic degradation by DPP-4. In addition, a modified fatty acid chain and the two PEG2 spacers turned out to be optimal for both in vitro and in vivo prolonged duration of action. In June 2021, the US Food and Drug Administration (FDA) approved semaglutide injection sold under the brand name Wegovy for long-term weight management in adults.